ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Metformin as a potential neuroprotective agent that influence Parkinson's disease.
Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.Frontiers in endocrinology · 2026Pooled it
- Metformin as a potential adjunct in the treatment of mild-to-moderate ulcerative colitis: a double-blind, randomized, placebo-controlled pilot study.Internal and emergency medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a significant neurodegenerative complication that impacts around 2% of individuals over the age of 65. The disease is characterized by a gradual decline of nigrostriatal dopaminergic neurons, which leads to physical impairments in individuals. Unfortunately, no drugs are currently available that can halt the progression and alleviate the symptoms of PD. Recently, there has been growing evidence to suggest a link between PD and type-2 diabetes (T2DM) which may provide a pharmacological explanation for this relation. In this review, we examine the literature that supports the pathological changes of Parkinson's disease, overlap of PD with diabetes mellitus, the neuro-protective mechanism of metformin including autophagy activation, α-synuclein build-up, inhibition of activity of mitochondrial complex I and anti-inflammatory action. We also explore the data of epidemiological investigations of metformin therapy in diabetic patients, exploring its potential benefits against age-related neuro-degeneration in both animal models and humans. Despite some conflicting results from animal and clinical research, we believe that the evidence suggests a potential role for metformin as a treatment for neuronal disorders, and further research is needed to establish this. In conclusion, our review provides insights into the connections between PD and T2DM, and suggests that metformin could be an effective therapy for neurodegenerative conditions.
Indexed as
Identifiers
40760214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.